Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
5,169,697
-
Total 13F shares
-
13,715,709
-
Share change
-
+3,194,621
-
Total reported value
-
$137,190,000
-
Price per share
-
$10.00
-
Number of holders
-
45
-
Value change
-
+$31,998,515
-
Number of buys
-
21
-
Number of sells
-
10
Institutional Holders of CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) as of Q1 2022
As of 31 Mar 2022,
CERo Therapeutics Holdings, Inc. - Common Stock, $0.0001 par value per share (CERO) was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
13,715,709 shares.
The largest 10 holders included
Beryl Capital Management LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, CANTOR FITZGERALD, L. P., MMCAP International Inc. SPC, Saba Capital Management, L.P., MARSHALL WACE, LLP, D. E. Shaw & Co., Inc., Polar Asset Management Partners Inc., and Periscope Capital Inc..
This page lists
45
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.